Lupin and Salix to collaborate in development of extended release Rifaximin product

Published: 6-Oct-2009
Regulatory Drug Delivery Pharmaceutical

Indian generic drugmaker Lupin has granted Salix Pharmaceuticals exclusive US rights to its bioadhesive drug delivery technology for use with gut-selective antibiotic Rifaximin.


Indian generic drugmaker Lupin has granted Salix Pharmaceuticals exclusive US rights to its bioadhesive drug delivery technology for use with gut-selective antibiotic Rifaximin.

Mumbai-based Lupin and Raleigh, NC-based Salix have entered into an agreement under which the two companies will collaborate in the development and commercialisation of an extended release product incorporating Rifaximin and utilising Lupin's proprietary bioadhesive technology.

Salix generated US$80m in revenue from Rifaximin, which it markets in the US as Xifaxan, in 2008. Lupin and Salix have entered into an exclusive agreement in the US for the supply of Rifaximin active pharmaceutical ingredient (API).

Salix has made a US$5m up-front payment and will make additional regulatory milestone payments to Lupin. In addition, Salix will pay royalties on net sales of the bioadhesive Rifaximin product to Lupin.

"We believe our proprietary bioadhesive drug delivery technology, which combines controlled-release as well as slowed gastrointestinal transit, would provide an extended release formulation of rifaximin that will be an important component of Salix's lifecycle management strategy for Rifaximin," said Nilesh Gupta, executive director of Lupin.

See more

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Read more
Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  3. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  4. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
  5. Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Drug Delivery

Tiziana receives grant for intranasal anti-CD3 monoclonal antibody therapy for spinal cord injury

The US Department of Defense awarded the biotechnology company a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI)
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Drug Delivery

Rice University scientists create hydrogel platform for precision, long-lasting drug delivery

The researchers have developed a peptide hydrogel system that slows and extends drug release, improving treatment adherence and efficacy across therapies ranging from tuberculosis medication to insulin
Subscribe now